Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients
Public ClinicalTrials.gov record NCT06279728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Medical Access Program for Datopotamab Deruxtecan (Dato-DXd, DS-1062a)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to Dato-DXd for eligible patients with previously treated advanced or metastatic EGFR mutated non-small cell lung cancer (NSCLC) who, in their treating physician's opinion, have an unmet clinical need, are unlikely to obtain optimal benefit from currently approved and commercially available drugs, and who cannot enter a suitable clinical trial.
Study identification
- NCT ID
- NCT06279728
- Recruitment status
- Approved For Marketing
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jul 2, 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Queen's Medical Center | Honolulu | Hawaii | 96813 | — |
| Graves Gilbert Clinic | Bowling Green | Kentucky | 42101 | — |
| Touro Infirmary - LCMC Health | New Orleans | Louisiana | 70115 | — |
| University of Maryland Medical Center Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Karmanos Cancer Institute (Barbara Ann Karmanos Cancer Hospital) | Detroit | Michigan | 48201 | — |
| Henry Ford Health | Detroit | Michigan | 48202 | — |
| Central Care Cancer Center | Bolivar | Missouri | 65613 | — |
| Overlook Medical Center Medical Diagnostic Associates Atlantic Medical Group | Summit | New Jersey | 07901 | — |
| New York Cancer & Blood Specialists | New York | New York | 10028 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| University of Texas Southwestern Medical | Dallas | Texas | 75390 | — |
| Houston Methodist Hospital Cancer Center | Houston | Texas | 77030 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06279728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 2, 2025 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06279728 live on ClinicalTrials.gov.